FDA Schedules Advisory Committee Review for Galleri Multi-Cancer Early Detection Blood Test

On September 23, a panel of independent genetic experts will gather in Washington to answer a question that could redefine routine healthcare: whether a single blood draw is ready to screen Americans for more than 50 types of cancer. The U.S. Food and Drug Administration has officially scheduled a Medical Devices Advisory Committee meeting to review the Premarket Approval application for GRAIL's Galleri test. If successful, it would become the first multi-cancer early detection (MCED) tool to secure full FDA authorization.[1][3]

For patients and primary care doctors, the review represents a critical juncture in the transition from experimental science to standard medical practice. Galleri works by analyzing cell-free DNA—fragments of genetic material that tumors shed into the bloodstream—and identifying specific methylation patterns to not only detect the presence of cancer but predict where in the body it originated. Currently, the test is available in the United States as a laboratory-developed test, meaning doctors can order it, but patients typically pay out-of-pocket costs approaching $900.[1][4]

FDA approval is the necessary key to unlocking broad accessibility. A congressional funding bill passed in January 2026 established a pathway for Medicare to cover FDA-approved MCED tests for individuals aged 50 to 65 starting in 2029, provided they demonstrate clear clinical benefit. Securing the agency's formal nod would transform Galleri from a niche, self-pay option into a foundational component of preventative care for millions of older adults.[1][4]

However, the advisory committee will have to navigate a complex and somewhat contested clinical data landscape. GRAIL's submission relies heavily on the PATHFINDER 2 study in the United States and the massive 142,000-person NHS-Galleri trial in the United Kingdom. Earlier this year, the UK trial revealed that the test missed its primary endpoint: it did not produce a statistically significant reduction in the combined rate of stage 3 and 4 cancer diagnoses compared to standard care.[2]

Despite missing that top-line goal, the underlying data offered compelling signals of clinical utility that the panel will weigh carefully. After three years of screening, the relative incidence of stage 4 cancers alone fell by 14 percent, while the detection of highly treatable stage 1 and 2 cancers increased by 16 percent. For clinical optimists, this shift toward earlier-stage detection is exactly what a screening tool is supposed to achieve, even if the overall late-stage burden has not yet dramatically collapsed.[2][4]

The FDA is not strictly bound by its advisory committees, but it follows their recommendations approximately 80 percent of the time. The September 23 meeting will feature public testimony, rigorous statistical debate, and a final vote that will likely set the regulatory standard not just for GRAIL, but for a wave of competing MCED tests currently in development by companies like Abbott.[1][2]

For the general public, the most practical takeaway is that MCED tests are designed to complement, rather than replace, established preventative care. Even if Galleri secures FDA approval in early 2027 as the company projects, health officials emphasize that patients must continue their routine mammograms, colonoscopies, and cervical screenings. These blood tests are a powerful new layer of defense aimed primarily at the 70 percent of cancer deaths caused by malignancies that currently lack any standard screening guidelines.[1]

As the September review approaches, the medical community remains cautiously optimistic. The promise of catching aggressive cancers before symptoms arise is one of the most sought-after goals in modern medicine. The FDA's task will be to determine if the current iteration of the technology is reliable enough to deploy on a population scale without triggering a wave of false positives, unnecessary biopsies, and patient anxiety.[2][3][4]